Decreasing the Burden While Increasing the Interval: Emerging Approaches in Treatment of AMD and DME healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
58 Biggest Movers From Yesterday msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Search jobs Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
CAMBRIDGE, Mass. (BUSINESS WIRE) Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company’s Board of Directors.
“I am pleased to welcome Georges to Gemini’s Board of Directors during this important time in our Company’s maturation, as we advance our lead program into the next stages of clinical development,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. “Georges’ broad management experience and proven track record of commercial and product development success will be invaluable as we continue to advance our pipeline of novel precision medicines.”
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.